bioeq’s second product FYB203 is a biosimilar of aflibercept (Eylea®) which was licensed by Santo Holding from Formycon AG in May 2015. Similarly to Lucentis®, Eylea® is prescribed for the treatment of neovascular age-related macular degeneration (neovascular AMD) and other serious eye conditions. The development of this biosimilar is at an early stage and under the terms of the license bioeq will both, supervise the pharmaceutical development conducted by Formycon and carry out the clinical development and registration of FYB203. The introduction of FYB203 biosimilar to the market is anticipated in the U.S. in 2023 and in Europe in 2025. The expected global market size for aflibercept in 2022 is estimated to be 7.4 bn USD (Evaluate Ltd, 2016).